Shoulder Innovations Reports 58% Revenue Growth in Third Quarter 2025
Shoulder Innovations Inc. reported a 58% revenue growth in Q3 2025, generating $11.8 million. The company sold 1,584 implant systems, a 53% increase from the previous year. With a gross margin of 76.2%, Shoulder Innovations expanded its I-Series product line and received FDA clearance for new fracture indications. Management raised the full-year revenue guidance following a 37% growth in the first half of the year.
Shoulder Innovations Inc. reported its financial results for the third quarter ended September 30, 2025. The company generated revenue of $11.8 million in the third quarter, representing a 58% increase over the same quarter last year. Shoulder Innovations sold 1,584 total implant systems, a 53% increase compared to the prior year quarter. The company achieved a gross margin of 76.2% for the period. Additionally, the company expanded its I-Series humeral stem product line with the full commercial launch of the InSet™ 70 and received FDA 510(k) clearance to expand the I-Series humeral stem product line to include certain fracture indications. Management indicated that first-half year-over-year revenue growth was 37%, which expanded to 58% in the third quarter, leading to an increase in the company’s full-year revenue guidance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shoulder Innovations Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: FL21618) on November 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
